This is a Phase IIa, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary TB to assess the early bactericidal activity of telacebec (Q203). Posted to clinicaltrials.gov June 21, 2018 NCT03563599 As of March 19, 2019, emrollment complete.
Primary Outcome Measures :
- The EBA (early bactericidal activity) of telacebec (Q203) [ Time Frame: Days 0 to 14 post dose ]
The EBA determined by the rate of change in the time to positivity (TTP) in sputum over the periods Days 0 to 14
Comparator Rifafour e-275